Filing Flows › Korro Bio (KRRO) › Recalls, complaints & regulation
Korro Bio (KRRO): clinical trials
Korro Bio (KRRO) beyond its filings: 1 active clinical trial.
Korro Bio's latest quarter
Korro Bio, Q4 2025: revenue $1.3M (-43% year over year), net loss $50.0M, operating cash flow −$17.7M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Korro Bio have?
1 active study on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.